Drug Prices
-
340B, Alzheimer’s, Caught my eye, Drug Prices, Drug shortages, Medicare Advantage, State-based ReformCaught my eye — 1/26/24
Read more: Caught my eye — 1/26/24It has been fun to see the year really start to kick off this week with a bunch of policy releases. Shortages. Generic shortages are caused by a myriad of factors, but a big piece is the race to the bottom for prices. A fraction of a penny less and a contract shifts to another…
-
Caught my eye — 1/19/23
Read more: Caught my eye — 1/19/23A thoughtful piece on price hikes. Price hikes are the routine story of January. Look price hikes! But because net price hides behind discounts and rebates, the full story is seldom in media. Here is a story that is (finally) a little more balanced on price hikes (and decreases). It even talks about the new…
Latest news
Categories
- 340B (35)
- Affordable Care Act (4)
- Alzheimer's (5)
- Biosimilars (21)
- Caught my eye (63)
- Cell and Gene (1)
- Chevron Deference (2)
- CMMI (11)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (32)
- Drug shortages (9)
- DTC (2)
- Employers (7)
- Generics (5)
- Health Equity (3)
- Healthcare Costs (28)
- ICER (10)
- Importation (2)
- Inflation Reduction Act (48)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (6)
- Medicare Advantage (16)
- Medicare Negotiation (50)
- Medicare Part D (46)
- Medicare Transaction Facilitator (3)
- Medicare Transaction Facilitator (8)
- Obesity (21)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (29)
- Reference Pricing (6)
- State-based Reform (15)
- Supply Chain (2)
- Uncategorized (6)
- Utilization Management (1)
- Vaccines (4)
- Value (13)